NL-OMON42614
Completed
Not Applicable
A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study. - PRIORA PGx
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- RA
- Sponsor
- Takeda
- Enrollment
- 4
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The participant (or, when applicable, the participant\*s legally acceptable representative) voluntarily signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria
- •\-Participants who did not receive namilumab during the PRIORA study.
- •\-Participants without any response time point recorded 4\-week after the last dose of namilumab and beyond this time point
- •\-Participants who were excluded from post\-hoc analysis due to protocol violations during the previous PRIORA study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIEUCTR2007-001377-28-FRMerck Serono International S.A.
Active, not recruiting
Not Applicable
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIEUCTR2007-001377-28-NLMerck Serono International S.A.92
Withdrawn
Phase 4
Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with Raptiva (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).auto-immune diseasesthrombocytopenia1003553410003816NL-OMON32149Serono10
Recruiting
Not Applicable
Collection of blood samples for the evaluation of the analytical performance of two new in vitro test systems for tuberculosis diagnosticsA15-A19TuberculosisDRKS00027129R-Biopharm AG636
Completed
Not Applicable
Trial for collection of blood samples from healed Covid-19 patients - research and development of in-vitro diagnosticsSARS-CoV-2 infectionCovid-19U07.1COVID-19, virus identifiedDRKS00022406R-Biopharm AG50